Noticias de ATOS_US

Noticias del mercado

Últimas noticias sobre ATOS_US — 117 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ATOS_US ✕ 117 resultados
25/03/2026 ATOS_US — MarketScreener
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
25/03/2026 ATOS_US — GuruFocus
Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss
25/03/2026 ATOS_US — PR Newswire
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
25/03/2026 ATOS_US — Stock Titan
R&D spending jumps as Atossa (NASDAQ: ATOS) advances (Z)-endoxifen programs
25/03/2026 ATOS_US — GuruFocus
Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss
25/03/2026 ATOS_US — Yahoo Finance
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
24/03/2026 ATOS_US — MarketScreener ES ← EN
El auditor de Atossa Therapeutics, Inc. plantea dudas sobre la existencia de una empresa en funcionamiento
20/03/2026 ATOS_US — TradingView
Atossa Therapeutics Inc expected to post a loss of $1.14 a share - Earnings Preview
19/03/2026 ATOS_US — PR Newswire
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
19/03/2026 ATOS_US — Morningstar
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
13/03/2026 ATOS_US — Traders Union ES ← EN
Atossa Therapeutics anuncia el lanzamiento de un programa DMD en etapa temprana para concienciar sobre enfermedades raras
12/03/2026 ATOS_US — PR Newswire
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
20/02/2026 ATOS_US — TipRanks
Atossa Therapeutics Launches New $50 Million ATM Program
20/02/2026 ATOS_US — Stock Titan
Atossa Therapeutics (NASDAQ: ATOS) launches $50M at-the-market stock offering
18/02/2026 ATOS_US — The Globe and Mail
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
17/02/2026 ATOS_US — TradingView
Atossa Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
17/02/2026 ATOS_US — TipRanks
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

Página 6 de 6

keyboard_arrow_up